-
EX-ANTE HEALTH ECONOMIC EVALUATION OF PERSONALIZED CARE PATHWAYS FOR ICU PATIENTS WITH INFLUENZA-ASSOCIATED PULMONARY ASPERGILLOSIS USING DISCRETE-EVENT SIMULATION
Aug 11, 2026, 17:16 PM -
ECONOMIC AND SOCIETAL BURDEN OF LUPUS NEPHRITIS IN LATIN AMERICA (LATAM): A MULTICOUNTRY ANALYSIS INCLUDING DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSSES
Aug 11, 2026, 17:16 PM -
THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT BILIARY TRACT CANCER IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Aug 11, 2026, 17:16 PM -
EVALUATING THE FEASIBILITY OF INDIRECT TREATMENT COMPARISONS IN PATIENTS WITH EPNEC TREATED IN SECOND-LINE AND BEYOND (2L+): A GUIDELINE-INFORMED SYSTEMATIC LITERATURE REVIEW AND FEASIBILITY ASSESSMENT
Aug 11, 2026, 17:16 PM -
ECONOMIC AND ORGANIZATIONAL IMPACT OF PRECLINICAL TYPE 1 DIABETES SCREENING IN FRANCE: RESULTS FROM AN ORGANIZATIONAL AND BUDGET IMPACT MODEL
Aug 11, 2026, 17:16 PM -
COST-UTILITY ANALYSIS OF RIBOCICLIB PLUS LETROZOLE VERSUS LETROZOLE MONOTHERAPY IN PREMENOPAUSAL AND PERIMENOPAUSAL WOMEN WITH HR+/HER2 ADVANCED BREAST CANCER: A MARKOV MODEL-BASED EVALUATION FROM AN INDIAN HEALTHCARE PERSPECTIVE
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF STRATEGIES TO PREVENT RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION AMONG INFANTS IN AUSTRIA
Aug 11, 2026, 17:16 PM -
BEYOND THE HEALTHCARE BUDGET: INDIRECT COSTS AS A MAJOR DRIVER OF THE ECONOMIC BURDEN OF CHRONIC DISEASES IN POLAND
Aug 11, 2026, 17:16 PM -
COMPARISON OF CASE-MIX GROUP AND ICD-10-CA-BASED APPROACHES FOR ADVERSE EVENT COST ESTIMATION IN CANADA
Aug 11, 2026, 17:16 PM -
METRELEPTIN EVIDENCE ACROSS CLINICALLY MEANINGFUL HEALTH-STATE TRANSITIONS IN GENERALIZED LIPODYSTROPHY: A MARKOV-BASED MCDA APPROACH
Aug 11, 2026, 17:16 PM -
EXPANDING THE SCOPE: THE SUSTAIN-OBS GOES INTERNATIONAL
Aug 11, 2026, 17:16 PM -
BUDGETIMPACT AND COST CONSEQUENCES OF REZAFUNGIN ADOPTION VERSUS DAILY ECHINOCANDINS FOR INVASIVE CANDIDIASIS IN SAUDI ARABIA
Aug 11, 2026, 17:16 PM -
BEYOND COST-EFFECTIVENESS: ESTIMATING THE SOCIAL VALUE OF PALBOCICLIB OVER ITS LIFECYCLE
Aug 11, 2026, 17:16 PM -
FROM EVIDENCE TO ACCESS: REIMBURSEMENT AND FUNDING BARRIERS FOR INNOVATIVE PERIPHERAL NEUROPATHIC PAIN TREATMENTS IN SOUTH KOREA
Aug 11, 2026, 17:16 PM -
FIFTEEN YEARS OF GERMAN HTA (AMNOG): TRENDS AND DRIVERS OF "NO ADDED BENEFIT"
Aug 11, 2026, 17:16 PM -
UNCERTAINITY IN PIVOTAL CLINICAL TRIALS AND REGULATORY OUTCOME IN EUROPE
Aug 11, 2026, 17:16 PM -
EVALUATING THE IMPACT OF FRANCE'S DEROGATORY DIRECT ACCESS SCHEME:INSIGHTS FROM THE PUBLIC HOSPITALS OF PARIS (AP-HP) FRAMEWORK
Aug 11, 2026, 17:16 PM -
EVALUATION OF EVIDENCE SOURCE AND ANALYSES TYPE PRESENTED IN RARE DISEASE NICE SUBMISSIONS AS INCLUSION IN JCA APPROACHES
Aug 11, 2026, 17:16 PM -
GREECE'S STRUCTURAL CO-PAYMENT BURDEN OF PATIENTS WITH MULTIMORBIDITY—A 13-COUNTRY EUROPEAN COMPARISON
Aug 11, 2026, 17:16 PM -
WHEN EVIDENCE IS NON-RANDOMIZED: HTA DECISIONS IN ATMPS ASSESSMENTS. A CROSS-AGENCY TARGETED REVIEW
Aug 11, 2026, 17:16 PM
